Discussing End-of-Life Care With a Patient

Dostarlimab/chemotherapy elicited a 31% decrease in the risk of death compared with placebo/chemotherapy in locally advanced/recurrent endometrial cancer.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Progression-free survival and objective response rate outcomes favored the tisotumab vedotin arm in the China subpopulation of the innovaTV 301 study.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

UGN-102 elicited complete responses in 79.6% of patients with non–muscle-invasive bladder cancer at 3 months in the ENVISION trial.

A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.